QOL Assessment in Rheumatoid Arthritis 84 含 SP.et al The reliability 45. JH.A J.ct al 46. 品物 6.Jaeschke B.Simge cinaCo 47. 48K m2006M367:65 Rm 二尚微费 Qual 地品8e 2age 52. and 33.F DR. global alth 54.Rit 5. 4 b)Ipackage insert].North Chicago (IL 58. insert].Horsham (PA) e1993Mar324 -6 np URL:http d20070t1 xate.Arthriti 37. or M i n the m24Ap504r1051-65 ents.Med Care 20 u:7 60.Han C et al.The ct of intlix URL: esearch. 6( 08Jul161 6 Tug ith a Med Ca 4 D. ny D.et al.The He 63.Farah F. tions.Health Qual Life Outcomes 2003:(1-13 JRheumatol 2006 Ap:33(4:665-70 2008 Adis Data Information BV.All rights resorved conomics2008:26(100 QOL Assessment in Rheumatoid Arthritis 845 22. Brazier J, Roberts J, Deverill M. The estimation of a preference- 43. Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the based measure of health from the SF-36. J Health Econ 2002 economic evaluation of health care programmes. 2nd ed. Ox￾Mar; 21 (2): 271-92 ford (NY): Oxford University Press, 1997 23. de Jong Z, van der Heijde D, McKenna SP, et al. The reliability 44. Duru G, Auray JP, Beresniak A, et al. Limitations of the and construct validity of the RAQoL: a rheumatoid arthritis- methods used for calculating quality-adjusted life-year values. specific quality of life instrument. Br J Rheumatol 1997 Aug; Pharmacoeconomics 2002; 20 (7): 463-73 36 (8): 878-83 45. Meenan RF, Mason JH, Anderson JJ, et al. AIMS2: the content and properties of a revised and expanded Arthritis Impact 24. The EuroQol group. A new facility for the measurement of Measurement Scales Health Status Questionnaire. Arthritis health-related quality of life. Health Policy 1999; 16: 199-208 Rheum 1992 Jan; 35 (1): 1-10 25. Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating 46. Cox SR, McWilliams L, Massy-Westropp N, et al. Adaptation clinically significant differences in quality of life outcomes. of the RAQoL for use in Australia. Rheumatol Int 2007 May; Qual Life Res 2005 Mar; 14 (2): 285-95 27 (7): 661-6 26. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: 47. Tammaru M, McKenna SP, Meads DM, et al. Adaptation of the ascertaining the minimal clinically important difference. Con- rheumatoid arthritis quality of life scale for Estonia. Rheu- trol Clin Trials 1989 Dec; 10 (4): 407-15 matol Int 2006 May; 26 (7): 655-62 27. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the 48. Kutlay S, Kucukdeveci AA, Gonul D, et al. Adaptation and clinical significance of health status measures. Mayo Clin Proc validation of the Turkish version of the Rheumatoid Arthritis 2002 Apr; 77 (4): 371-83 Quality of Life Scale. Rheumatol Int 2003 Jan; 23 (1): 21-6 28. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient 49. Russak SM, Croft Jr JD, Furst DE, et al. The use of rheumatoid outcome in arthritis. Arthritis Rheum 1980 Feb; 23 (2): 137-45 arthritis health-related quality of life patient questionnaires in 29. Bruce B, Fries JF. The Stanford Health Assessment Question- clinical practice: lessons learned. Arthritis Rheum 2003 Aug naire: dimensions and practical applications. Health Qual Life 15; 49 (4): 574-84 Outcomes 2003 Jun 9; 1 (1): 20 50. Proceedings from the sixth biannual conference of the Outcome Measures in Rheumatoid Arthritis Clinical Trials group 30. Wells GA, Tugwell P, Kraag GR, et al. Minimum important (OMERACT); 2002 May; Cairns, Australia. difference between patients with rheumatoid arthritis: the pa- 51. Saag KG. OMERACT 6 brings new perspectives to rheumatolo- tient’s perspective. J Rheumatol 1993 Mar; 20 (3): 557-60 gy measurement research. J Rheumatol 2003 Apr; 30 (4): 31. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally 639-41 important changes in generic and disease-specific health-relat- 52. Greenwood MC, Hakim AJ, Carson E, et al. Touch-screen ed quality of life questionnaires in clinical trials of rheumatoid computer systems in the rheumatology clinic offer a reliable arthritis. Arthritis Rheum 2000 Jul; 43 (7): 1478-87 and user-friendly means of collecting quality-of-life and out- 32. Hewlett S, Smith AP, Kirwan JR. Measuring the meaning of come data from patients with rheumatoid arthritis. Rheu- disability in rheumatoid arthritis: the Personal Impact Health matology (Oxford) 2006 Jan; 45 (1): 66-71 Assessment Questionnaire (PI HAQ). Ann Rheum Dis 2002 53. Orencia (abatacept) [package insert]. Princeton (NJ): Bristol- Nov; 61 (11): 986-93 Myers Squibb, 2007 33. Fries JF, Ramey DR. ‘Arthritis specific’ global health analog 54. Rituxan (rituximab) [package insert]. South San Francisco scales assess ‘generic’ health related quality-of-life in patients (CA): Biogen Idec Inc. and Genentech, Inc., 2007 with rheumatoid arthritis. J Rheumatol 1997 Sep; 24 (9): 55. Kineret (anakinra) [package insert]. Thousand Oaks (CA): 1697-702 Amgen, Inc., 2006 34. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form 56. Enbrel (etanercept) [package insert]. Thousand Oaks (CA): Im- health survey (SF-36): I. Conceptual framework and item munex Corp., 2006 selection. Med Care 1992 Jun; 30 (6): 473-83 57. Humira (adalimumab) [package insert]. North Chicago (IL): 35. McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-Item Abbott Laboratories, 2005 Short-Form Health Survey (SF-36): II. Psychometric and clin- 58. Remicade (infliximab) [package insert]. Horsham (PA): ical tests of validity in measuring physical and mental health Centocor Inc., 2007 constructs. Med Care 1993 Mar; 31 (3): 247-63 59. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improve- 36. PROQUOLID. Patient-reported outcome and quality of life ment over two years in physical function, structural damage, instruments data base home page [online]. Available from and signs and symptoms among patients with rheumatoid URL: http://www.quolid.com [Accessed 2007 Oct 11] arthritis treated with infliximab and methotrexate. Arthritis 37. Conner-Spady B, Suarez-Almazor ME. Variation in the estima- Rheum 2004 Apr; 50 (4): 1051-65 tion of quality-adjusted life-years by different preference- 60. Han C, Smolen JS, Kavanaugh A, et al. The impact of inflix￾based instruments. Med Care 2003 Jul; 41 (7): 791-801 imab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007; 9 (5): R103 38. The EuroQol Group. EuroQol: a new facility for the measure￾ment of health-related quality of life. Health Policy 1990 Dec; [online]. Available from URL: http://arthritis-research.com/ content/pdf/ar2306.pdf [Accessed 2008 Jul 16] 16 (3): 199-208 61. Torrance GW, Tugwell P, Amorosi S, et al. Improvement in 39. Brooks R. EuroQol: the current state of play. Health Policy 1996 health utility among patients with rheumatoid arthritis treated Jul; 37 (1): 53-72 with adalimumab (a human anti-TNF monoclonal antibody) 40. Marra CA, Esdaile JM, Guh D, et al. A comparison of four plus methotrexate. Rheumatology (Oxford) 2004 Jun; 43 (6): indirect methods of assessing utility values in rheumatoid 712-8 arthritis. Med Care 2004; 42 (11): 1125-31 62. van der Heijde D, Klareskog L, Singh A, et al. Patient reported 41. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and outcomes in a trial of combination therapy with etanercept and single-attribute utility functions for the health utilities index methotrexate for rheumatoid arthritis: the TEMPO trial. Ann mark 3 system. Med Care 2002 Feb; 40 (2): 113-28 Rheum Dis 2006 Mar; 65 (3): 328-34 42. Horsman J, Furlong W, Feeny D, et al. The Health Utilities 63. Farahani P, Levine M, Gaebel K, et al. Community-based Index (HUI): concepts, measurement properties and applica- evaluation of etanercept in patients with rheumatoid arthritis. tions. Health Qual Life Outcomes 2003; 1 (1): 1-13 J Rheumatol 2006 Apr; 33 (4): 665-70 © 2008 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2008; 26 (10)